Biotech firm Synaptogenix has made an unexpected move into the crypto space, revealing its first acquisition of Bittensor (TAO) as part of a broader treasury diversification strategy.
The company confirmed the purchase in an official statement, marking a shift in focus toward digital assets, with a particular emphasis on crypto projects tied to artificial intelligence. Though the exact size of the TAO investment remains undisclosed, Synaptogenix previously hinted it could allocate up to $10 million toward the asset.
To manage its new crypto position, Synaptogenix has partnered with BitGo, which will handle custody, trading, and staking services. CEO Joshua Silverman credited strategy advisor James Altucher for steering the firm toward TAO, calling it a long-term bet on both income generation and AI-driven blockchain innovation.
“Our alliance with BitGo and the choice to invest in TAO reflect our belief in the asset’s potential to deliver value over time,” Silverman said, positioning the move as a step toward long-term shareholder growth.
As institutional players build exposure to familiar names like Bitcoin and Ethereum, Synaptogenix’s pivot toward TAO places it among the early adopters of next-generation AI-integrated crypto assets.
As airdrop controversies continue to shake confidence across the crypto sector, Eclipse Labs is taking proactive steps to distance itself from recent missteps by other projects.
Crypto infrastructure firm Bit Digital is making a bold strategic pivot, abandoning Bitcoin mining entirely in favor of Ethereum staking and asset management.
Coinbase has taken another step toward boosting DeFi participation by launching wrapped versions of Cardano and Litecoin on its Base Layer 2 network.
Investor attention in the crypto market appears to be rotating toward a new mix of altcoins.